1 The L-arginine-NO pathway has been implicated in the vasorelaxant eect of 17-b-oestradiol. Here we have addressed the involvement of two distinct activation steps of endothelial nitric oxide synthase (eNOS) in the 17-b-oestradiol-induced vasorelaxant eect on rat aortic rings. 2 Rat aortic rings contracted with phenylephrine (PE) 1 mM relaxed in a concentration related fashion to 17-b-oestradiol water soluble cyclodextrin-encapsulated (E2) only when endothelium was present. The pure anti-oestrogen of E2 receptor ICI 182,780 (20 mM) signi®cantly inhibited E2-induced vasorelaxation. 3 Geldanamycin (10 mM), a speci®c inhibitor of heat shock protein 90 (hsp90) and N o -nitro-Larginine-methyl ester (L-NAME, 100 mM), a nitric oxide synthase inhibitor, signi®cantly inhibited E2-induced vasorelaxation. 4 Incubation of rat aortic rings up to 6 h with LY 294002 (25 mM), a speci®c inhibitor of PI(3)K akt/pkb pathway reduced E2-induced vasorelaxation. 5 Incubation of rat isolated aorta with E2, induced prostacyclin (PGI 2 ) release. PGI 2 levels, measured as 6-keto PGF 1a , were abolished by ibuprofen (10 mM), both L-NAME and GA did not in¯uence basal or E2-stimulated PGI 2 con®rming the speci®city of these two compounds on eNOS pathway. 6
Introduction
Oestrogen is a female sex hormone that produces several biological eects through binding to the oestrogen receptors (ER) a and b (Green et al., 1986; Kuiper & Gustafsson, 1997; Paech et al., 1997) . Oestrogen, as other steroids, acts through genomic and non-genomic mechanisms; in particular the non-genomic modulation of physiological and pathophysiological processes has been the object of several studies in the past few years. Oestrogen displays signi®cant cardioprotective actions and contributes to the sex dierence in the risk of cardiovascular diseases (Sullivan et al., 1988; Adams et al., 1990; Kauser et al., 1997) . The bene®cial eects of oestrogen on cardiovascular system is partially due to a direct vasodilatory eect of this hormone on arteries (Bush et al., 1987) . Indeed, several studies showed a direct relationship between oestrogen and nitric oxide release in conductance and resistance arteries both in vitro and in vivo (Rosselli et al., 1995; Sudhir et al., 1995; Huang et al., 1998) . In vitro in cultured endothelial cells, oestrogen activates the endothelial isoform of nitric oxide synthase (eNOS) (Caulin-Glaser et al., 1997) and stimulates heat shock protein 90-eNOS association in human vascular endothelial cells suggesting an involvement of hsp90 in the rapid, oestrogen receptor-mediated modulation of eNOS (Russell et al., 2000) . In vivo oestrogen restores endothelium-dependent coronary vasodilatation in post-menopausal women and this action has also been ascribed to nitric oxide .
The ER resides in a transcriptionally inactive state with a complex of chaperone proteins within the nucleus (at equilibrium) of the target cells (Pratt & Toft, 1997; Defranco, 2000;  for review see Falkenstein et al. 2000) . Following the binding of the hormone, two molecules of hsp90 and the immunophillin hsp56, that maintain the receptor in an inactive form, dissociate from the receptor (Pratt & Toft, 1997 ) that changes its conformation initiating a cascade of events leading to the activation of speci®c DNA sequence regulating gene transcription (Kumar et al., 1987; Gallo & Kaufman, 1997) . In bovine aortic endothelial cells, acute exposure to 17-b-oestradiol increases NO production through ERa localized in caveolae British Journal of Pharmacology (2002) 135, 1695 ± 1700 ã 2002 Nature Publishing Group All rights reserved 0007 ± 1188/02 $25.00 www.nature.com/bjp *Author for correspondence; E-mail: cirino@unina.it (Kim et al., 1999) , a cholesterol and sphingolipid-rich microdomain of the plasmalemma (Garcia-Cardena et al., 1996) where eNOS also resides . eNOS is the nitric oxide synthase isoform responsible of NO release in vascular endothelial cells. NO is a potent vasodilator factor that plays several roles in physiological processes such as the control of basal tone of vessels, vascular remodelling (Rudic et al., 2000) and angiogenesis (Papapetropoulos et al., 1997a; Morbidelli et al., 1996) . Association of hsp90 with eNOS enhances the enzyme activity, as demonstrated by the ®nding that geldanamycin, a speci®c inhibitor of hsp90, attenuates both agoniststimulated production of nitric oxide and endotheliumdependent relaxation of isolated blood vessels (GarciaCardena et al., 1998) . Finally, it has also been shown that the serine/threonine protein kinase (akt/pkb) is involved in the complex mechanism involving eNOS activation (Dimmeler et al., 1999; Fulton et al., 1999; Zeng & Quon, 1996; Papapetropoulos et al., 1997b) by phosphorylating the enzyme (Fulton et al., 1999; Dimmeler et al., 1999) .
Based on the above evidence, here we have sought to investigate the molecular mechanism involved in 17-boestradiol-induced vasorelaxation, i.e eNOS phosphorylation and coupling to hsp90, in isolated rat aortic rings by using speci®c pharmacological tools.
Methods

Drugs
Acetylcholine (ACh), L-phenylephrine (PE), N o -nitro-Larginine methyl ester (L-NAME), ibuprofen, tetraethylammonium (TEA), 17-b-oestradiol water soluble cyclodextriencapsulated (E2), LY 294002, polyethylene glycol 400 (PEG), dimethyl sulphoxide (DMSO) were purchased from Sigma Chemical Co. (Milano, Italy), ICI 182,780 was purchased from Tocris Cookson Ltd. (Bristol, U.K.), Dulbecco's modi®ed Eagle medium (DMEM), L-glutamine, penicillin and streptomycin were purchased from Hy-Clone (Road Logan, UT, U.S.A.), geldanamycin (GA) was a generous gift of the Drug Synthesis & Chemistry Branch, Development Therapeutics program, Division of Cancer treatment at the National Cancer Institute (Bethesda, MD, U.S.A.). GA was dissolved in a solution of distilled water dH 2 O/PEG (1/1), ICI 182,780 was dissolved in PEG, TEA and L-NAME in dH 2 O. The volume added to the organ bath for each compound was 2.5 ml, except for TEA that was 25 ml.
Tissue preparation
Male Wistar rats (Charles River, 250 ± 300 g) of 8 ± 10 weeks of age were sacri®ced and thoracic aorta was rapidly dissected and cleaned from fat and connective tissue. Rings of 2 ± 3 mm length were cut and placed in organ baths (2.5 ml) ®lled with oxygenated (95% O 2 -5% CO 2 ) Krebs solution at 378C and mounted to isometric force transducers (type 7006, Ugo Basile, Comerio, Italy) and connected to a Graphtec linearcorder (WR3310, Japan). The composition of the Krebs solution was as follows (mol l 71 ): NaCl 0.118, KCl 0.0047, MgCl 2 0.0012, KH 2 PO 4 0.0012, CaCl 2 0.0025, NaHCO 3 0.025 and glucose 0.010. Rings were initially stretched until a resting tension of 0.5 g was reached and allowed to equilibrate for at least 30 min during which tension was adjusted, when necessary, to 0.5 g and bathing solution was periodically changed. In a preliminary study a resting tension of 0.5 g was found to develop the optimal tension to stimulation with contracting agents.
Experimental protocol
In each experiment rings were ®rstly challenged with PE (10 76 M) until the responses were reproducible. In order to verify the integrity of the endothelium, ACh cumulative concentration ± response curve (10   78   73610 75 M) was performed on PE-precontracted rings. Vessels that relaxed less than 75% were discarded. Selected rings were then contracted with PE (10 76 M), once plateau was reached, a cumulative concentration ± response curve to E2 (10   78   73610 75 M) was performed. In another set of experiments, rings were denuded of the endothelium and E2 cumulative concentration ± response curve was performed.
Drug treatments
A preliminary study on the optimal incubation time of the drug treatments and concentration was carried out (data not shown). The experiments were then performed by using the optimal incubation time and concentrations as speci®ed for each protocol reported below. Aortic rings were standardized with PE (10 76 M) and performing a cumulative concentration response to Ach (10   78   73610 75 M) was performed. The experimental protocols performed were: (1) GA (3610
76
, 10 75 and 3610 75 M), L-NAME (10
and ICI 182,780 (2610 75 M) were added in the organ baths on PE-precontracted rings. After 15 min of incubation, a cumulative concentration ± response curve to E2 was performed; (2) TEA (10 72 M) was added in the organ baths; after 60 min, the rings were contracted with PE (10 76 M) and a cumulative concentration ± response curve to E2 was performed; (3) Ibuprofen (10 75 M) was added to the Krebs solution and ACh and a cumulative concentration ± response curve to E2 was performed.
LY 294002 treatments
Thoracic aorta was dissected, placed in sterile PBS and cleaned of fat and connective tissue. Rings, of the same size as described above, were cut and placed in a 24 multiwell plate with 980 ml DMEM solution (containing penicillin 100 U ml 71 , streptomycin 100 mg ml 71 and Lglutamine 2610 73 M) in the presence of LY 294002 (2.5610 75 M) or vehicle (DMSO; 20 ml). This concentration of DMSO in DMEM (2%) is the maximal that can be added without aecting tissue functionality (data not shown). Thereafter, the plate was placed at 378C in an incubator (Mod. BB6220, Heraeus Instruments, Germany) with humidi®ed air (5% CO 2 /95% O 2 ). After 1, 3, 6 and 16 h of incubation rings were washed extensively with Krebs and then mounted in organ baths, as described above (Bucci et al., 2000) .
Prostacyclin (PGI 2 ) release from rat aorta
Rat aortas were removed as described above, cut in rings, weighted and placed in a 24 multiwell plate with 500 ml of gassed Krebs solution. In each well were added GA, L-NAME or vehicles using the same concentrations used for the organ bath studies and placed in an incubator with humidi®ed air (5% CO 2 /95% O 2 ) at 378C (Mod. BB6220, Heraeus Instruments, Germany) for 15 min. After this incubation period 100 ml of supernatant were removed in order to evaluate the basal release of PGI 2 from incubation wells set for this purpose. In all the remaining wells, E2 (10 75 M) was added and left in contact for another additional 30 min. Thereafter, 100 ml aliquots were taken to assess PGI 2 levels. Prostacyclin levels were measured as stable breakdown product, 6-keto-PGF 1a , by enzymatic immunoassay (EIA, Cayman Chemical) and expressed as mg ml 71 per mg of tissue (wet weight) (Bucci et al., 2000) . EIA was performed according to the manufacturer's directions. Data are the mean+s.e.mean of ®ve separate experiments.
Statistical analysis
All data were expressed as mean+s.e.mean. Statistical analysis was performed by using 2-way ANOVA and paired or unpaired Student's t-test where appropriate. Dierences were considered statistically signi®cant when P was less than 0.05.
Results
17-b-oestradiol induced endothelium-dependent vasodilatation
In presence of endothelium, E2 induced a concentrationdependent vasodilatation on PE pre-contracted rings. When endothelium was removed E2 was ineective (Figure 1 ).
Effect of inhibitors on E2-induced vasodilatation
GA at the concentration of 10 75 M after 15 min of incubation signi®cantly reduced E2-induced vasodilatation when compared to the vehicle (dH 2 O/PEG 1/1, Figure 2A ).
The lowest concentration (3610 76 M) was inactive while the concentration of 3610 75 M did not further inhibit E2-induced vasorelaxation (data not shown). Similarly, L-NAME at the concentration of 10 74 M, after 15 min of incubation, signi®cantly inhibited E2-induced vasodilatation, when compared to the vehicle (dH 2 O), at the same extent of GA ( Figure 2B ). In presence of ibuprofen (10 75 M) E2-induced vasodilatation was also signi®cantly inhibited (P50.05, data not shown).
In order to evaluate if calcium-activated potassium channels could be implicated in E2-induced vasorelaxation, Figure 1 Cumulative concentration-response curves to 17-b-oestradiol (E2) in rat aortic rings with and without endothelium. Data are shown as means+s.e mean; n=6 for each group. rings were incubated with tetraethylammonium (TEA) at the concentration of 10 72 M for 60 min. This treatment did not aect E2-induced vasodilatation ( Figure 2C ). In these conditions TEA neither induced contraction nor enhanced signi®cantly PE-induced contraction (data not shown).
Effect of oestrogens receptor pure antagonist ICI 182,780 on E2-induced vasodilatation in rat aorta
To demonstrate that the E2-induced vasorelaxation on aortic rings was mediated through the interaction of E2 with its receptor, ICI 182,780, a pure anti-oestrogen of E2 receptor was used. When aortic rings were incubated with ICI 182,780 at the concentration of 2610 75 M for 15 min, inhibition of E2-induced vasodilatation occurred (Figure 3) . E2 induces prostacyclin (PGI 2 ) release from rat aorta PGI 2 levels, measured as 6-keto-PGF 1a , were signi®cantly increased following 30 min of incubation with E2 (10 75 M, Figure 5 ). GA and L-NAME did not in¯uence basal or E2-stimulated PGI 2 levels produced by rat aortic rings. On the other hand, ibuprofen treatment completely blocked E2-induced PGI 2 release ( Figure 5) . LY 294002 was not tested since DMSO at the lowest amount needed to dissolve the drug interfered with the assay.
Effect of LY 294002 on E2-induced vasodilatation
Discussion
In this study we have examined the involvement of L-arginine NO pathway in the vasodilatory eect of 17-b-oestradiol on rat aortic rings. To perform this study we used water soluble E2 cyclodestrin-encapsulated, since 17-b-oestradiol is soluble only in organic solvents that usually interfere in tissue bath experiments. The ®rst experiments we performed was the endothelium removal to con®rm that E2-induced vasodilatation is endothelium-dependent. This ®nding is in agreement with another study where following endothelium removal, rat arteriole lost their ability to modify their diameter following E2 stimulation (Huang et al., 2000) . To further gain insights into the mechanisms involved we used a pharmacological approach. For this purpose we used L-NAME that acts as false substrate for nitric oxide synthase blunting NO release in endothelium (Southan & Szabo, 1996) , geldanamycin, a speci®c inhibitor of eNOS activation through its binding to hsp90 (Garcia-Cardena et al., 1998) and LY 294002, a speci®c inhibitor of phosphatidylinositol-3-OH kinase (PI(3)K), that regulates through akt, NO release in endothelial cells by eNOS phosphorylation (Fulton et al., 1999) .
L-NAME strongly reduced E2-induced vasorelaxation suggesting that nitric oxide is the main vasorelaxing factor responsible for E2-induced vasodilatation in this condition. However, this inhibitor widely used to show NO involvement, being a false substrate, does not give information on the possible molecular mechanism(s) involved.
It is known that hsp90 coordinates the tracking and the regulation of several signalling proteins, in particular it has been shown that hsp90 associates with eNOS enhancing the activation of this enzyme (Garcia-Cardena et al., 1998) . Incubation of aortic rings with GA reduced ACh-induced vasorelaxation indicating the involvement of hsp90 in agoniststimulated production of nitric oxide (Garcia-Cardena et al., 75 M) or vehicle (DMSO) as described in conditioned medium. After incubation rings were washed repeatedly and then mounted in organ baths to perform the experiments. n=5 for each group; **P50.01, ***P50.001 vs vehicle group. British Journal of Pharmacology vol 135 (7) 1998). In our experiments GA, at the same concentration and incubation time that inhibits ACh-induced vasorelaxation, signi®cantly reduced E2-induced vasorelaxation. This eect was already maximal at the concentration of 10 75 M and did not further increase at the concentration of GA to 3610
A lower concentration, such as 3610 76 M, had no eect on E2-induced vasorelaxation. This phenomenon could be explained considering how GA acts on eNOS activation. GA speci®cally binds to hsp90, hindering the interaction between eNOS and hsp90 (Garcia-Cardena et al., 1998) . It has been also shown that GA 10 75 M reduces ACh-induced vasorelaxation in rat aortic rings (Garcia-Cardena et al., 1998) . Most likely, GA 10 75 M is the concentration that subtracts an amount of hsp90 molecules sucient to interfere with the activation mechanism of the enzyme and this eect is not further increased with GA 3610 75 M. For the opposite reason GA 3610 76 M did not aect E2-induced vasodilatation e.g. there is still enough free hsp90 able to interact with eNOS. Thus, it is feasible that when E2 binds to its receptor liberation of two molecules of hsp90 occurs that in turn could activate eNOS.
Another mechanism through which eNOS is activated and that has been recently described is its activation through phosphorylation. Indeed, recently Fulton et al. (1999) showed that the serine/threonine protein kinase akt (protein kinase B) can directly phosphorylate eNOS on serine 1179 and activate the enzyme, leading to NO production. They have shown that incubating endothelial cells with LY 294002, a speci®c inhibitor of PI(3)K, there was a partial block of NO release. For this purpose LY 294002, a speci®c inhibitor of PI(3)K was used to further characterize the mechanism of the activation of eNOS as responsible of E2-induced vasorelaxation. In our experiments by incubating rat aortic rings with LY 294002 (2.5610 75 M) there was a remarkable inhibition of E2-induced vasorelaxation. In particular we performed a time-course of LY 294002 eect on E2-induced vasorelaxation. Following 1 and 3 h of incubation LY 294002 did not aect E2-induced vasorelaxation, after 6 h of incubation instead LY 294002 strongly inhibited E2-induced vasorelaxation and this eect increased up to 16 h of incubation. Thus these results, taken all together, indicate that eNOS activation, through both mechanisms, is essential in E2-induced vasorelaxation.
It has been shown that E2 activates the arachidonic acid cascade and that E2 stimulates cyclo-oxygenase derived products in cultured rat aortic smooth muscle cells and in isolated rat aorta (Chang et al., 1981 (Chang et al., , 1983 . Conversely, in male rat aortic endothelial cells (RAEC) oestrogen increases PGI 2 release but not through COX activation (Myers et al., 1996) suggesting that E2 stimulation can increase endogenous PGI 2 release in RAEC. Our data also con®rm an involvement of PGI 2 in E2-mediated vasorelaxation since ibuprofen reduced signi®cantly, E2-induced vasorelaxation, as also shown by others (Chang et al., 1983) . GA and L-NAME did not modify PGI 2 release while ibuprofen completely abolished basal and E2-stimulated PGI 2 release implying that the inhibitory eect is not mediated through COX inhibition. These results further stress the speci®city of these compounds on two critical steps of the L-arginine-NO pathway.
Involvement of potassium channels in E2-induced vasodilatory eect can be ruled out since pre-treatment of the rings with the unselective calcium-activated potassium channels blocker TEA was ineective on E2-induced vasorelaxation. TEA has been used at the concentration described to block Ach-induced vasorelaxation in rat isolated renal arteries (Jiang et al., 2000) and at this same concentration, in our experimental conditions, inhibited ACh-induced vasodilatory eect (data not shown). Concerning this particular eect it has been already shown that TEA dose-dependently inhibited E2-induced uterine vasodilation without aecting mean arterial pressure, heart rate and uterine blood¯ow in ovariectomized nonpregnant ewes (Rosenfeld et al., 2000) implying a dierent action of E2 on the vascular system compared to uterus.
We have further investigated if the eect of E2 is due to the interaction with its receptor(s). Our data show that in aortic rings treated with ICI 182,780, an oestrogen receptor pure antagonist, E2-induced vasorelaxation was inhibited. If the incubation was increased up to 1 h, when the compound acts by blocking the E2 genomic eect (Wakeling et al., 1991) , ICI 182,780 was ineective. It is known that the complex ER ± ICI 182,780 has a shorter half-life when compared to ER ± E2 complex due to an increased ER turn over-provoked by ICI 182,780 (Dauvais et al. 1992 ). This particular mechanism could explain why, when incubated for a longer time, ICI 182,780 did not aect E2-induced vasorelaxation. On the other hand, using shorter incubation times e.g. up to 15 min there was a signi®cant inhibition of E2-induced vasorelaxation due to the fact that ICI 182,780, in this condition, exerts mainly its eect by preventing E2 ± ER interaction.
In conclusion, we have shown that once E2 binds to its receptor, eNOS is stimulated to release NO. eNOS activation process involves its coupling to hsp90 and phosphorylation. In fact, by using LY 294002, a speci®c inhibitor of PI(3)K pathway, and GA, an hsp90 binding substance, a marked reduction of E2-induced vasodilatation occurred. In addition we have also shown that this eect is also linked to E2 ± ER interaction in a non-genomic fashion. To our knowledge, this is the ®rst demonstration that the L-arginine-NO pathway component of E2-induced vasorelaxation is linked to both eNOS phosphorylation through akt/pkb pathway and coupling to hsp90.
